CPA

DRUG2 trials

Sponsors

Clear Passage Therapies, Inc, ImmunoVaccine Technologies, Inc. (IMV Inc.)

Conditions

Endocrine System DiseasesFSH HypersecretionInfertilityRefractory Diffuse Large B-cell LymphomaRelapsed Diffuse Large B-cell Lymphoma

Phase 2

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

RecruitingNCT04920617

ImmunoVaccine Technologies, Inc. (IMV Inc.)Refractory Diffuse Large B-cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma

Start: 2021-06-18End: 2025-04-30Target: 102Updated: 2023-04-07

Unknown Phase

Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women

TerminatedNCT02027168

Clear Passage Therapies, IncEndocrine System Diseases, FSH Hypersecretion, Infertility

Start: 2013-02-28End: 2015-01-31Updated: 2015-01-26

Related Papers

Vitalize Trial: A Phase 2b, Open-Label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of the Novel Immunotherapeutic, Maveropepimut-S, and Pembrolizumab with and without Intermittent Low-Dose Cyclophosphamide, in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood2022-11-15

PB2138: VITALIZE TRIAL: A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED PARALLEL-GROUP, TWO-STAGE, STUDY OF MAVEROPEPIMUT-S, PEMBROLIZUMAB, WITH OR WITHOUT INTERMITTENT LOW-DOSE CYCLOPHOSPHAMIDE, IN R/R DLBLC

HemaSphere2022-06-01